The independent source for health policy research, polling, and news.
821-840 of 1,322 results
An estimated 1.25 million Americans have Type 1 diabetes and cannot live without insulin. Sen. Kamala Harris’ claim that 1 in 4 diabetes patients cannot afford their insulin is a shockingly high number, so we decided to dig into the sparse data.
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
California Gov. Gavin Newsom claims that his state is “leading the nation in holding drug companies accountable and fighting prescription drug prices.” Is that really the case?
It’s as shady as it sounds.
Whistleblower lawsuits accuse Tennessee chain of bilking millions from Medicare for unnecessary urine drug tests.
After dozens of health care workers were charged with illegally prescribing opioids in Appalachia, local health agencies are trying to make sure chronic pain patients don't fall through the cracks.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
It’s "within spitting distance of something that’s true," said one health economist. But our fact check found it wasn't quite there.
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
What to know about PBMs and rebates ahead of the Senate drug price hearing on — you guessed it — PBMs.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Beneficiaries pay 25 percent of the price of their brand-name drugs until they reach $5,100 in out-of-pocket costs. After that, their obligation drops to 5 percent. But it never disappears.
Only by the bizarre logic of the U.S. pharmaceutical industry does this drug count as any kind of generic.
Executive editor Damon Darlin takes a spin as host of “The Friday Breeze,” whirling through a week of health care news so you don’t have to.
Stephanie Armour of The Wall Street Journal, Alice Ollstein of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss the suggested cuts to health programs in President Donald Trump’s budget proposal, the latest on lawsuits challenging work requirements for Medicaid enrollees and the FDA’s crackdown on e-cigarettes. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week.
Eli Lilly released a half-price generic version of its own short-acting insulin. At $137.35 per vial, the generic insulin is priced at about the same level as Humalog was in 2012.
Newsletter editor Brianna Labuskes wades through hundreds of health articles from the week so you don’t have to.
Clear differences of opinion emerged between Democrats and Republicans during a House Ways and Means subcommittee hearing about how to make prescription drugs more affordable in the Medicare program.
© 2026 KFF